Keertan Dheda

List of Publications by Year
in descending order

283 papers	26,675 citations	9756 73 h-index	7718 150 g-index
292 all docs	292 docs citations	292 times ranked	30835 citing authors

#	Article	IF	Citations
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
2	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine, 2021, 384, 1885-1898.	13.9	1,077
3	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
4	Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet, The, 2010, 375, 1830-1843.	6.3	866
5	Validation of housekeeping genes for normalizing RNA expression in real-time PCR. BioTechniques, 2004, 37, 112-119.	0.8	838
6	Tuberculosis. Nature Reviews Disease Primers, 2016, 2, 16076.	18.1	830
7	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clinical Microbiology Reviews, 2014, 27, 3-20.	5.7	662
8	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine, 2021, 384, 1899-1909.	13.9	541
9	Tuberculosis. Lancet, The, 2016, 387, 1211-1226.	6.3	480
10	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 291-360.	5.2	459
11	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	6.3	452
12	Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet, The, 2014, 383, 424-435.	6.3	379
13	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clinical Microbiology Reviews, 2018, 31, .	5.7	353
14	Functional Capacity of <i>Mycobacterium tuberculosis</i>-Specific T Cell Responses in Humans Is Associated with Mycobacterial Load. Journal of Immunology, 2011, 187, 2222-2232.	0.4	305
15	Supervised and Unsupervised Self-Testing for HIV in High- and Low-Risk Populations: A Systematic Review. PLoS Medicine, 2013, 10, e1001414.	3.9	285
16	Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 132-140.	2.5	283
17	A standardised method for interpreting the association between mutations and phenotypic drug resistance in<i>Mycobacterium tuberculosis</i>. European Respiratory Journal, 2017, 50, 1701354.	3.1	273
18	Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nature Genetics, 2018, 50, 307-316.	9.4	271

#	ARTICLE	IF	CITATIONS
19	Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respiratory Medicine,the, 2014, 2, 321-338.	5.2	237
20	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. European Respiratory Journal, 2017, 49, 1700387.	3.1	233
21	Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet, The, 2010, 375, 1798-1807.	6.3	225
22	New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis. Expert Review of Molecular Diagnostics, 2006, 6, 413-422.	1.5	223
23	Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet, The, 2014, 383, 1230-1239.	6.3	211
24	Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet, The, 2016, 387, 1187-1197.	6.3	211
25	Lung Remodeling in Pulmonary Tuberculosis. Journal of Infectious Diseases, 2005, 192, 1201-1209.	1.9	207
26	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine,the, 2017, 5, 785-794.	5.2	201
27	What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?. PLoS ONE, 2013, 8, e54587.	1.1	187
28	Management of drug-resistant tuberculosis. Lancet, The, 2019, 394, 953-966.	6.3	186
29	Outcome of HIVâ€Associated Tuberculosis in the Era of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 190, 1670-1676.	1.9	181
30	Within-Subject Variability of Interferon-g Assay Results for Tuberculosis and Boosting Effect of Tuberculin Skin Testing: A Systematic Review. PLoS ONE, 2009, 4, e8517.	1.1	171
31	Within-Subject Variability and Boosting of T-Cell Interferon-Î³ Responses after Tuberculin Skin Testing. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 49-58.	2.5	169
32	T-cell interferon-Î³ release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Current Opinion in Pulmonary Medicine, 2009, 15, 188-200.	1.2	169
33	New tools and emerging technologies for the diagnosis of tuberculosis: Part II. Active tuberculosis and drug resistance. Expert Review of Molecular Diagnostics, 2006, 6, 423-432.	1.5	168
34	IL-4 in tuberculosis: implications for vaccine design. Trends in Immunology, 2004, 25, 483-488.	2.9	167
35	T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infectious Diseases, The, 2007, 7, 428-438.	4.6	167
36	Drugâ€resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology, 2018, 23, 656-673.	1.3	159

#	Article	IF	Citations
37	The immunology of tuberculosis: From bench to bedside. Respirology, 2010, 15, 433-450.	1.3	155
38	Xpert^{Â®}MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. The Cochrane Library, 2018, 8, CD012768.	1.5	153
39	The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study. EClinicalMedicine, 2020, 28, 100570.	3.2	152
40	High Incidence of Hospital Admissions With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Among South African Health Care Workers. Annals of Internal Medicine, 2010, 153, 516.	2.0	151
41	Immune responses to tuberculosis in developing countries: implications for new vaccines. Nature Reviews Immunology, 2005, 5, 661-667.	10.6	149
42	Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Receiving Antiretroviral Therapy. Drugs, 2008, 68, 191-208.	4.9	144
43	Diagnostic Accuracy of Quantitative PCR (Xpert MTB/RIF) for Tuberculous Meningitis in a High Burden Setting: A Prospective Study. PLoS Medicine, 2013, 10, e1001536.	3.9	142
44	Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?. Lancet Infectious Diseases, The, 2014, 14, 527-532.	4.6	141
45	Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assayâ€"A Clinical Validation Study. PLoS ONE, 2011, 6, e20458.	1.1	140
46	HIV-1 Infection Impairs the Bronchoalveolar T-Cell Response to Mycobacteria. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1262-1270.	2.5	138
47	Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1208-1219.	2.5	130
48	Pointâ€ofâ€care diagnosis of tuberculosis: Past, present and future. Respirology, 2013, 18, 217-232.	1.3	127
49	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV,the, 2021, 8, e568-e580.	2.1	124
50	Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. European Respiratory Journal, 2012, 40, 1211-1220.	3.1	117
51	Clinical Utility of a Commercial LAM-ELISA Assay for TB Diagnosis in HIV-Infected Patients Using Urine and Sputum Samples. PLoS ONE, 2010, 5, e9848.	1.1	117
52	Do digital innovations for HIV and sexually transmitted infections work? Results from a systematic review (1996-2017). BMJ Open, 2017, 7, e017604.	0.8	116
53	Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. Aids, 2005, 19, 2038-2041.	1.0	112
54	Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?. Clinical Infectious Diseases, 2016, 62, 995-1001.	2.9	112

#	ARTICLE	IF	CITATIONS
55	What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?. Indian Journal of Medical Research, 2019, 149, 309.	0.4	110
56	Utility of the antigen-specific interferon-?? assay for the management of tuberculosis. Current Opinion in Pulmonary Medicine, 2005, 11, 195-202.	1.2	109
57	Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respiratory Medicine,the, 2017, 5, 269-281.	5.2	106
58	Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Current Opinion in Pulmonary Medicine, 2010, 16, 262-270.	1.2	100
59	Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Scientific Reports, 2015, 4, 5658.	1.6	100
60	An automated tuberculosis screening strategy combining X-ray-based computer-aided detection and clinical information. Scientific Reports, 2016, 6, 25265.	1.6	100
61	The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respiratory Medicine,the, 2022, 10, 603-622.	5.2	99
62	Human Lung Immunity against *Mycobacterium tuberculosis*. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 696-707.	2.5	98
63	Anaerobic Bacterial Fermentation Products Increase Tuberculosis Risk in Antiretroviral-Drug-Treated HIV Patients. Cell Host and Microbe, 2017, 21, 530-537.e4.	5.1	95
64	Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax, 2013, 68, 1043-1051.	2.7	93
65	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respiratory Medicine,the, 2019, 7, 820-826.	5.2	92
66	Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. European Respiratory Journal, 2018, 51, 1800544.	3.1	91
67	The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. Lancet, The, 2012, 379, 773-775.	6.3	88
68	Detecting active pulmonary tuberculosis with a breath test using nanomaterial-based sensors. European Respiratory Journal, 2014, 43, 1522-1525.	3.1	88
69	Comparison of Quantitative Techniques including Xpert MTB/RIF to Evaluate Mycobacterial Burden. PLoS ONE, 2011, 6, e28815.	1.1	87
70	Utility of quantitative T-cell responses versus unstimulated interferon-Â for the diagnosis of pleural tuberculosis. European Respiratory Journal, 2009, 34, 1118-1126.	3.1	86
71	Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. Journal of Occupational Medicine and Toxicology, 2006, 1, 7.	0.9	85
72	Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study. The Lancet Global Health, 2013, 1, e97-e104.	2.9	82

#	ARTICLE	IF	CITATIONS
73	Lethal interaction: the colliding epidemics of tobacco and tuberculosis. Expert Review of Anti-Infective Therapy, 2007, 5, 385-391.	2.0	80
74	Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulmonary Medicine, 2010, 10, 7.	0.8	79
75	False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes. Journal of Clinical Microbiology, 2018, 56, .	1.8	78
76	The Diagnostic Accuracy of Urine-Based Xpert MTB/RIF in HIV-Infected Hospitalized Patients Who Are Smear-Negative or Sputum Scarce. PLoS ONE, 2012, 7, e39966.	1.1	75
77	Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-γ in a high burden setting: a prospective study. BMC Medicine, 2014, 12, 101.	2.3	75
78	Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase. Scientific Reports, 2018, 8, 15382.	1.6	75
79	Will an Unsupervised Self-Testing Strategy for HIV Work in Health Care Workers of South Africa? A Cross Sectional Pilot Feasibility Study. PLoS ONE, 2013, 8, e79772.	1.1	73
80	The diagnostic accuracy of the GenoType^{Â®}MTBDR<i>sl</i>assay for the detection of resistance to second-line anti-tuberculosis drugs. , 2014, , CD010705.		72
81	Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis, 2011, 91, 587-593.	0.8	71
82	Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa. PLoS ONE, 2013, 8, e63057.	1.1	71
83	Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial. Lancet Infectious Diseases, The, 2017, 17, 441-450.	4.6	71
84	Clinical Diagnostic Utility of IP-10 and LAM Antigen Levels for the Diagnosis of Tuberculous Pleural Effusions in a High Burden Setting. PLoS ONE, 2009, 4, e4689.	1.1	70
85	Regulatory T Cells Attenuate Mycobacterial Stasis in Alveolar and Blood-derived Macrophages from Patients with Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1249-1258.	2.5	68
86	Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infectious Diseases, 2013, 13, 407.	1.3	68
87	Cigarette smoke impairs cytokine responses and BCG containment in alveolar macrophages. Thorax, 2014, 69, 363-370.	2.7	67
88	Cerebrospinal T-Cell Responses Aid in the Diagnosis of Tuberculous Meningitis in a Human Immunodeficiency Virusâ€" and Tuberculosis-Endemic Population. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 569-577.	2.5	65
89	Xpert MTB/RIF as a Measure of Sputum Bacillary Burden. Variation by HIV Status and Immunosuppression. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1426-1434.	2.5	64
90	Tuberculosis and Poncet's disease: the many faces of an old enemy. Lancet, The, 2016, 387, 618.	6.3	63

#	Article	IF	Citations
91	South African guideline for the management of community-acquired pneumonia in adults. Journal of Thoracic Disease, 2017, 9, 1469-1502.	0.6	63
92	Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Library, 2021, 2021, CD012768.	1.5	63
93	Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Tropical Medicine and International Health, 2010, 15, 1052-1066.	1.0	62
94	Automatic Detection of Tuberculosis in Chest Radiographs Using a Combination of Textural, Focal, and Shape Abnormality Analysis. IEEE Transactions on Medical Imaging, 2015, 34, 2429-2442.	5.4	62
95	Recombination in pe/ppe genes contributes to genetic variation in Mycobacterium tuberculosis lineages. BMC Genomics, 2016, 17, 151.	1.2	62
96	In VivoandIn VitroStudies of a Novel Cytokine, Interleukin 4Î´2, in Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 501-508.	2.5	60
97	Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?. European Respiratory Journal, 2012, 40, 161-168.	3.1	60
98	Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN-Î³ for the evaluation of pleural tuberculosis: a prospective cohort study. BMC Pulmonary Medicine, 2014, 14, 58.	0.8	60
99	Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Current Opinion in Rheumatology, 2011, 23, 377-384.	2.0	59
100	Scoring systems using chest radiographic features for the diagnosis of pulmonary tuberculosis in adults: a systematic review. European Respiratory Journal, 2013, 42, 480-494.	3.1	59
101	Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Review of Anti-Infective Therapy, 2012, 10, 475-486.	2.0	57
102	Selection and Application of ssDNA Aptamers to Detect Active TB from Sputum Samples. PLoS ONE, 2012, 7, e46862.	1.1	57
103	Interpretation of Mycobacterium tuberculosis antigen-specific IFN-Î³ release assays (T-SPOT.TB) and factors that may modulate test results. Journal of Infection, 2007, 55, 169-173.	1.7	56
104	The identification of tuberculosis biomarkers in human urine samples. European Respiratory Journal, 2014, 43, 1719-1729.	3.1	56
105	Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis. Science Advances, 2017, 3, e1701102.	4.7	56
106	Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis. Thorax, 2009, 64, 847-853.	2.7	55
107	Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Subâ€Saharan Africa. International Journal of Gynecology and Obstetrics, 2010, 108, 181-183.	1.0	54
108	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. The Lancet Global Health, 2019, 7, e191-e199.	2.9	53

#	Article	IF	Citations
109	Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial. Lancet Respiratory Medicine,the, 2013, 1, 471-478.	5.2	52
110	Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. European Respiratory Journal, 2016, 47, 919-928.	3.1	52
111	Recent controversies about <scp>MDR</scp> and <scp>XDRâ€TB</scp>: <scp>G</scp>lobal implementation of the <scp>WHO</scp> shorter <scp>MDRâ€TB</scp> regimen and bedaquiline for all with <scp>MDRâ€TB</scp>?. Respirology, 2018, 23, 36-45.	1.3	52
112	Viewpoint: Scientific dogmas, paradoxes and mysteries of latent <i>Mycobacterium tuberculosis</i> infection. Tropical Medicine and International Health, 2011, 16, 79-83.	1.0	51
113	Multidrug- and Extensively Drug-resistant Tuberculosis in Africa and South America: Epidemiology, Diagnosis and Management in Adults and Children. Clinics in Chest Medicine, 2009, 30, 667-683.	0.8	50
114	Extensively Drug-resistant Tuberculosis: Epidemiology and Management Challenges. Infectious Disease Clinics of North America, 2010, 24, 705-725.	1.9	50
115	A comparison of the conditional inference survival forest model to random survival forests based on a simulation study as well as on two applications with time-to-event data. BMC Medical Research Methodology, 2017, 17, 115.	1.4	50
116	Psychological distress and its relationship with non-adherence to TB treatment: a multicentre study. BMC Infectious Diseases, 2015, 15, 253.	1.3	49
117	Removing the bottleneck in whole genome sequencing of Mycobacterium tuberculosis for rapid drug resistance analysis: a call to action. International Journal of Infectious Diseases, 2017, 56, 130-135.	1.5	49
118	Comparison of a Clinical Prediction Rule and a LAM Antigen-Detection Assay for the Rapid Diagnosis of TBM in a High HIV Prevalence Setting. PLoS ONE, 2010, 5, e15664.	1.1	47
119	Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clinical Microbiology and Infection, 2017, 23, 131-140.	2.8	47
120	Transmission of drug-resistant tuberculosis in HIV-endemic settings. Lancet Infectious Diseases, The, 2019, 19, e77-e88.	4.6	47
121	In Vivo Molecular Dissection of the Effects of HIV-1 in Active Tuberculosis. PLoS Pathogens, 2016, 12, e1005469.	2.1	46
122	Aspergilloma and the surgeon. Journal of Thoracic Disease, 2014, 6, 202-9.	0.6	46
123	<i>Myobacterium tuberculosis</i> Induces Selective Up-Regulation of TLRs in the Mononuclear Leukocytes of Patients with Active Pulmonary Tuberculosis. Journal of Immunology, 2006, 176, 3010-3018.	0.4	45
124	The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates. Scientific Reports, 2016, 6, 17850.	1.6	45
125	<scp>d</scp>-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. Clinical Infectious Diseases, 2018, 67, S308-S316.	2.9	45
126	The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs. Genome Medicine, 2016, 8, 132.	3.6	44

#	Article	IF	Citations
127	The epidemiology of tuberculosis in health care workers in South Africa: a systematic review. BMC Health Services Research, 2016, 16, 416.	0.9	44
128	Diagnostic patch testing following tuberculosisâ€‌associated cutaneous adverse drug reactions induces systemic reactions in <scp>HIV</scp> â€‌infected persons. British Journal of Dermatology, 2016, 175, 150-156.	1.4	43
129	GenoType^{Â®} MTBDR<i>sl</i> assay for resistance to second-line anti-tuberculosis drugs. The Cochrane Library, 2016, 2016, CD010705.	1.5	42
130	Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control. Microbiology Spectrum, 2017, 5, .	1.2	42
131	C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial. PLoS ONE, 2018, 13, e0204554.	1.1	42
132	The Use of an Automated Quantitative Polymerase Chain Reaction (Xpert MTB/RIF) to Predict the Sputum Smear Status of Tuberculosis Patients. Clinical Infectious Diseases, 2012, 54, 384-388.	2.9	41
133	Incidence of occupational latent tuberculosis infection in South African healthcare workers. European Respiratory Journal, 2015, 45, 1364-1373.	3.1	41
134	Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. Tuberculosis, 2006, 86, 152-162.	0.8	40
135	Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Lancet Respiratory Medicine,the, 2015, 3, 621-630.	5.2	40
136	Guidance for Studies Evaluating the Accuracy of Biomarker-Based Nonsputum Tests to Diagnose Tuberculosis. Journal of Infectious Diseases, 2019, 220, S108-S115.	1.9	38
137	Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. Nature Medicine, 2020, 26, 1435-1443.	15.2	38
138	An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study). American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1214-1227.	2.5	38
139	Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. Lancet HIV,the, 2022, 9, e309-e322.	2.1	38
140	Utility of a novel lipoarabinomannan assay for the diagnosis of tuberculous meningitis in a resource-poor high-HIV prevalence setting. Cerebrospinal Fluid Research, 2009, 6, 13.	0.5	37
141	Differential Targeting of c-Maf, Bach-1, and Elmo-1 by microRNA-143 and microRNA-365 Promotes the Intracellular Growth of Mycobacterium tuberculosis in Alternatively IL-4/IL-13 Activated Macrophages. Frontiers in Immunology, 2019, 10, 421.	2.2	37
142	The medical and surgical treatment of drug-resistant tuberculosis. Journal of Thoracic Disease, 2014, 6, 186-95.	0.6	37
143	False-negative interferon-Î³ release assay results in active tuberculosis: a TBNET study. European Respiratory Journal, 2015, 45, 279-283.	3.1	36
144	Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings. European Respiratory Journal, 2014, 43, 185-194.	3.1	35

#	Article	IF	Citations
145	Chest X-ray Analysis With Deep Learning-Based Software as a Triage Test for Pulmonary Tuberculosis: An Individual Patient Data Meta-Analysis of Diagnostic Accuracy. Clinical Infectious Diseases, 2022, 74, 1390-1400.	2.9	35
146	Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. Journal of Thoracic Disease, 2018, 10, 3102-3118.	0.6	34
147	Development of a Simple Reliable Radiographic Scoring System to Aid the Diagnosis of Pulmonary Tuberculosis. PLoS ONE, 2013, 8, e54235.	1.1	34
148	Correlation of Mycobacterium Tuberculosis Specific and Non-Specific Quantitative Th1 T-Cell Responses with Bacillary Load in a High Burden Setting. PLoS ONE, 2012, 7, e37436.	1.1	33
149	Prospective Cohort Study on Performance of Cerebrospinal Fluid (CSF) Xpert MTB/RIF, CSF Lipoarabinomannan (LAM) Lateral Flow Assay (LFA), and Urine LAM LFA for Diagnosis of Tuberculous Meningitis in Zambia. Journal of Clinical Microbiology, 2019, 57, .	1.8	33
150	Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation. The Lancet Global Health, 2019, 7, e798-e807.	2.9	33
151	Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Tropical Medicine and International Health, 2010, 15, 1179-1184.	1.0	32
152	Same-Day Tools, Including Xpert Ultra and IRISA-TB, for Rapid Diagnosis of Pleural Tuberculosis: a Prospective Observational Study. Journal of Clinical Microbiology, 2019, 57, .	1.8	32
153	Can Point-of-Care Urine LAM Strip Testing for Tuberculosis Add Value to Clinical Decision Making in Hospitalised HIV-Infected Persons?. PLoS ONE, 2013, 8, e54875.	1.1	32
154	Correlation of Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis bacillary burden in high HIV burden areas of Southern Africa. Scientific Reports, 2018, 8, 5201.	1.6	31
155	Profiles of Volatile Biomarkers Detect Tuberculosis from Skin. Advanced Science, 2021, 8, e2100235.	5.6	31
156	Compounding diagnostic delays: a qualitative study of point‐of‐care testing in <scp>S</scp>outh <scp>A</scp>frica. Tropical Medicine and International Health, 2015, 20, 493-500.	1.0	30
157	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. Journal of Infection, 2019, 78, 35-39.	1.7	30
158	A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. European Respiratory Journal, 2020, 55, 1901181.	3.1	30
159	TB diagnostic tests: how do we figure out their costs?. Expert Review of Anti-Infective Therapy, 2009, 7, 723-733.	2.0	29
160	Novel Developments in the Epidemic of Human Immunodeficiency Virus and Tuberculosis Coinfection. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 987-997.	2.5	29
161	Use of Anti-Retroviral Therapy in Tuberculosis Patients on Second-Line Anti-TB Regimens: A Systematic Review. PLoS ONE, 2012, 7, e47370.	1.1	29
162	South African tobacco smoking cessation clinical practice guideline. South African Medical Journal, 2013, 103, 869.	0.2	29

#	Article	IF	Citations
163	Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	29
164	ICU-Associated Acinetobacter baumannii Colonisation/Infection in a High HIV-Prevalence Resource-Poor Setting. PLoS ONE, 2012, 7, e52452.	1.1	29
165	Regulatory T Cells Subvert Mycobacterial Containment in Patients Failing Extensively Drug-Resistant Tuberculosis Treatment. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 104-116.	2.5	28
166	A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guérin. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1277-1291.	2.5	28
167	Transcriptional profiling of innate and adaptive human immune responses to mycobacteria in the tuberculin skin test. European Journal of Immunology, 2011, 41, 3253-3260.	1.6	27
168	Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing. BMC Infectious Diseases, 2015, 15, 262.	1.3	27
169	Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 370-380.	2.5	27
170	Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis. Journal of Infectious Diseases, 2017, 216, S654-S661.	1.9	26
171	The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis. Clinical Infectious Diseases, 2018, 67, S336-S341.	2.9	26
172	Expression of a novel cytokine, IL-4delta2, in HIV and HIV–tuberculosis co-infection. Aids, 2005, 19, 1601-1606.	1.0	25
173	Comparison of Amplicor and GeneXpert MTB/RIF Tests for Diagnosis of Tuberculous Meningitis. Journal of Clinical Microbiology, 2014, 52, 3777-3780.	1.8	25
174	Evaluation of a Urine-Based Rapid Molecular Diagnostic Test with Potential to Be Used at Point-of-Care for Pulmonary Tuberculosis. Journal of Molecular Diagnostics, 2018, 20, 215-224.	1.2	25
175	EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa. BMC Public Health, 2013, 13, 258.	1.2	24
176	Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study. PLoS Medicine, 2019, 16, e1002776.	3.9	23
177	An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells. Cancer Immunology, Immunotherapy, 2019, 68, 71-83.	2.0	23
178	*N*-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and *N*-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	23
179	IL-4 subverts mycobacterial containment in *Mycobacterium tuberculosis*-infected human macrophages. European Respiratory Journal, 2019, 54, 1802242.	3.1	22
180	TRIM5α and TRIM22 Are Differentially Regulated According to HIV-1 Infection Phase and Compartment. Journal of Virology, 2014, 88, 4291-4303.	1.5	21

#	Article	IF	Citations
181	Diagnosing tuberculosis in hospitalized HIV-infected individuals who cannot produce sputum: is urine lipoarabinomannan testing the answer?. BMC Infectious Diseases, 2017, 17, 803.	1.3	21
182	Performance of the TB-LAMP diagnostic assay in reference laboratories: Results from a multicentre study. International Journal of Infectious Diseases, 2018, 68, 44-49.	1.5	21
183	Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen. International Journal of Infectious Diseases, 2019, 85, 74-79.	1.5	21
184	Alone But Supported: A Qualitative Study of an HIV Self-testing App in an Observational Cohort Study in South Africa. AIDS and Behavior, 2020, 24, 467-474.	1.4	21
185	Relationship between chemokine receptor expression, chemokine levels and HIV â€‘1 replication in the lungs of persons exposed to M ycobacterium tuberculosis. European Journal of Immunology, 2013, 43, 540-549.	1.6	19
186	Time for the Global Rollout of Endoscopic Lung Volume Reduction. Respiration, 2015, 90, 430-440.	1.2	19
187	High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis. PLoS ONE, 2015, 10, e0123655.	1.1	19
188	Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases. Journal of Antimicrobial Chemotherapy, 2015, 70, 2648-2651.	1.3	19
189	Making HIV testing work at the point of care in South Africa: a qualitative study of diagnostic practices. BMC Health Services Research, 2017, 17, 408.	0.9	19
190	Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	19
191	A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic. BMC Medicine, 2020, 18, 24.	2.3	19
192	The stability of mRNA encoding IL-4 is increased in pulmonary tuberculosis, while stability of mRNA encoding the antagonistic splice variant, IL-4Î´2, is not. Tuberculosis, 2007, 87, 237-241.	0.8	18
193	Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis. Journal of Infectious Diseases, 2019, 219, 975-985.	1.9	18
194	Lichenoid drug reaction to antituberculosis drugs treated through with topical steroids and phototherapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 2535-2537.	1.3	17
195	Pan-tuberculosis regimens: an argument against. Lancet Respiratory Medicine,the, 2018, 6, 240-242.	5.2	17
196	Impact of a personalised, digital, HIV self-testing app-based program on linkages and new infections in the township populations of South Africa. BMJ Global Health, 2021, 6, e006032.	2.0	17
197	Increased Production of IL-4 and IL-12p40 from Bronchoalveolar Lavage Cells Are Biomarkers of Mycobacterium tuberculosis in the Sputum. PLoS ONE, 2013, 8, e59461.	1.1	16
198	Disrupting a cycle of mistrust: A constructivist grounded theory study on patient-provider trust in TB care. Social Science and Medicine, 2019, 240, 112578.	1.8	16

#	ARTICLE	IF	CITATIONS
199	Recommendations for lung cancer screening in Southern Africa. Journal of Thoracic Disease, 2019, 11, 3696-3703.	0.6	16
200	Comparative performance characteristics of the urine lipoarabinomannan strip test and sputum smear microscopy in hospitalized HIV-infected patients with suspected tuberculosis in Harare, Zimbabwe. BMC Infectious Diseases, 2015, 16, 20.	1.3	15
201	HIV associated Lymphocytic Interstitial Pneumonia: a clinical, histological and radiographic study from an HIV endemic resource-poor setting. BMC Pulmonary Medicine, 2015, 15, 38.	0.8	15
202	The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis. Scientific Reports, 2016, 6, 32924.	1.6	15
203	Early morning urine collection to improve urinary lateral flow LAM assay sensitivity in hospitalised patients with HIV-TB co-infection. BMC Infectious Diseases, 2017, 17, 339.	1.3	15
204	Relationship between chest radiographic characteristics, sputum bacterial load, and treatment outcomes in patients with extensively drug-resistant tuberculosis. International Journal of Infectious Diseases, 2019, 79, 65-71.	1.5	15
205	Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemic setting. International Journal of Infectious Diseases, 2020, 95, 246-252.	1.5	15
206	Comparative Utility of Cytokine Levels and Quantitative RD-1-Specific T Cell Responses for Rapid Immunodiagnosis of Tuberculous Meningitis. Journal of Clinical Microbiology, 2011, 49, 3971-3976.	1.8	14
207	Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients. Open Forum Infectious Diseases, 2016, 3, ofw130.	0.4	14
208	A Survey on Use of Rapid Tests and Tuberculosis Diagnostic Practices by Primary Health Care Providers in South Africa: Implications for the Development of New Point-of-Care Tests. PLoS ONE, 2015, 10, e0141453.	1.1	14
209	Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial. Scientific Reports, 2018, 8, 8828.	1.6	13
210	Once-a-week tigecycline for the treatment of drug-resistant TB. Journal of Antimicrobial Chemotherapy, 2019, 74, 1607-1617.	1.3	13
211	Feasibility and Diagnostic Utility of Antigen-Specific Interferon-γ Responses for Rapid Immunodiagnosis of Tuberculosis Using Induced Sputum. PLoS ONE, 2010, 5, e10389.	1.1	12
212	HIV self-testing strategy: the middle road. Expert Review of Molecular Diagnostics, 2013, 13, 639-642.	1.5	12
213	Revising the definition of extensively drug-resistant tuberculosis. Lancet Respiratory Medicine,the, 2018, 6, 893-895.	5.2	12
214	Xpert MTB/RIF test for tuberculosis. Lancet, The, 2011, 378, 481.	6.3	11
215	Biologic therapy for rheumatoid arthritis in developing countries--a place for non-TNF inhibitors as first-line treatment?. Rheumatology, 2015, 54, 208-209.	0.9	11
216	Time to revise WHO-recommended definitions of MDR-TB treatment outcomes. Lancet Respiratory Medicine,the, 2018, 6, 246-248.	5.2	11

#	Article	IF	Citations
217	Tuberculous meningitis is associated with higher cerebrospinal HIV-1 viral loads compared to other HIV-1-associated meningitides. PLoS ONE, 2018, 13, e0192060.	1.1	11
218	Evaluating Latent Tuberculosis Infection Test Performance Using Latent Class Analysis in a TB and HIV Endemic Setting. International Journal of Environmental Research and Public Health, 2019, 16, 2912.	1.2	11
219	The Great Masquerader: Tuberculosis Presenting as Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 592-604.	0.8	11
220	Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa. The Lancet Global Health, 2014, 2, e554-e556.	2.9	10
221	Lifestyle, attitudes and needs of uncured <scp>XDR</scp>â€‹<scp>TB</scp> patients living in the communities of South Africa: a qualitative study. Tropical Medicine and International Health, 2015, 20, 1155-1161.	1.0	10
222	Management of chronic obstructive pulmonary diseaseâ€"A position statement of the South African Thoracic Society: 2019 update. Journal of Thoracic Disease, 2019, 11, 4408-4427.	0.6	10
223	Smoking is Not Beneficial for Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 821-821.	2.5	9
224	Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB. ERJ Open Research, 2019, 5, 00046-2019.	1.1	9
225	The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. European Respiratory Journal, 2019, 53, 1802089.	3.1	9
226	Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0138121.	1.4	9
227	Bronchial Thermoplasty Global Registry (BTGR): 2-year results. BMJ Open, 2021, 11, e053854.	0.8	9
228	Better treatment of XDR tuberculosis needed in South Africa â€" Author's reply. Lancet, The, 2014, 384, 582.	6.3	8
229	Predictors of discordant latent tuberculosis infection test results amongst South African health care workers. BMC Infectious Diseases, 2019, 19, 131.	1.3	8
230	â€˜You're only there on the phoneâ€™? A qualitative exploration of community, affect and agential capacity in HIV selfâ€testing using a smartphone app. Sociology of Health and Illness, 2021, 43, 591-606.	1.1	8
231	The Frequency and Effect of Granulocytic Myeloid-Derived Suppressor Cells on Mycobacterial Survival in Patients With Tuberculosis: A Preliminary Report. Frontiers in Immunology, 2021, 12, 676679.	2.2	8
232	Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society. Journal of Thoracic Disease, 2016, 8, 3711-3719.	0.6	7
233	The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates<i>Mycobacterium tuberculosisâ€"</i>Specific Host Immunity Through the Glucocorticoid Receptor. Journal of Infectious Diseases, 2019, 219, 1329-1337.	1.9	7
234	Diagnosis of COVID-19: Considerations, Controversies and Challenges in South Africa. Wits Journal of Clinical Medicine, 2020, 2, 3.	0.0	7

#	ARTICLE	IF	CITATIONS
235	Longitudinal assessment of health related quality of life of HIV infected patients treated for tuberculosis and HIV in a high burden setting. Quality of Life Research, 2016, 25, 3067-3076.	1.5	6
236	Design and use of mouse control DNA for DNA biomarker extraction and PCR detection from urine: Application for transrenal Mycobacterium tuberculosis DNA detection. Journal of Microbiological Methods, 2017, 136, 65-70.	0.7	6
237	Urine lipoarabinomannan (LAM) and antimicrobial usage in seriously-ill HIV-infected patients with sputum smear-negative pulmonary tuberculosis. Journal of Thoracic Disease, 2019, 11, 3505-3514.	0.6	6
238	An Optimal Diagnostic Strategy for Tuberculosis in Hospitalized HIV-Infected Patients Using GeneXpert MTB/RIF and Alere Determine TB LAM Ag. Journal of Clinical Microbiology, 2020, 58, .	1.8	6
239	Characteristics of Xpert MTB/RIF-Negative Patients With Pulmonary Tuberculosis. Clinical Infectious Diseases, 2012, 55, 472-473.	2.9	5
240	Urine antigen test for diagnosis of HIV-associated tuberculosis. Lancet Infectious Diseases, The, 2012, 12, 825.	4.6	5
241	Getting bang for buck in the latent tuberculosis care cascade. Lancet Infectious Diseases, The, 2016, 16, 1209-1210.	4.6	5
242	Peripheral T Cell Interferon-Î³ Responses and Latent Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 97-98.	2.5	5
243	World TB Day 2010 - New innovations are required for enhancing the global fight against Tuberculosis: the â€˜Captain of all these men of deathâ€™. Tropical Medicine and International Health, 2010, 15, 274-276.	1.0	4
244	Profiles of Volatile Biomarkers Detect Tuberculosis from Skin (Adv. Sci. 15/2021). Advanced Science, 2021, 8, 2170093.	5.6	4
245	Type 2 Cytokines in Respiratory Syncytial Virus Bronchiolitis. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1167-1168.	2.5	4
246	Sleepiness score-specific outcomes of a novel tongue repositioning procedure for the treatment of continuous positive airway pressure-resistant obstructive sleep apnea. Annals of Maxillofacial Surgery, 2019, 9, 28.	0.2	4
247	Crosstalk between the thoracic physician and the surgeon: perspectives on pulmonary infections, malignancy and chest surgery. Journal of Thoracic Disease, 2014, 6, 181.	0.6	4
248	Rationalizing Use of Fluoroquinolones and Pyrazinamide in the Battle against Multidrug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 10-11.	2.5	3
249	Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT.Â®TB and QFT-GIT). Journal of Thoracic Disease, 2016, 8, 482-489.	0.6	3
250	Latent Tuberculosis Infectionâ€"associated Immunodiagnostic Test Responses as Biomarkers of Incipient Tuberculosis: Fruitful or Futile?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 895-898.	2.5	3
251	Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1169, 122467.	1.2	3
252	Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting. BMC Infectious Diseases, 2021, 21, 99.	1.3	3

#	ARTICLE	IF	CITATIONS
253	Accelerate investment and action to find the missing patients with tuberculosis. Lancet, The, 2022, 399, 2086-2088.	6.3	3
254	Quantitative Pulmonary T-Cell Responses for the Diagnosis of Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 289-289.	2.5	2
255	Sanatoria for drug-resistant tuberculosis: an outdated response â€" Authors' reply. Lancet, The, 2012, 379, 2148-2149.	6.3	2
256	Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	2
257	High mortality among patients hospitalized for drugâ€resistant tuberculosis with acquired secondâ€line drug resistance and high <scp>HIV</scp> prevalence. HIV Medicine, 2022, 23, 1085-1097.	1.0	2
258	Impact of tuberculosis treatment and antiretroviral therapy on serial RD-1-specific quantitative T-cell readouts (QuantiFERON-TB Gold In-Tube), and relationship to treatment-related outcomes and bacterial burden. International Journal of Infectious Diseases, 2015, 36, 46-53.	1.5	1
259	Endoscopic Valve Therapy: A New Therapeutic Approach for Otherwise Incurable Tuberculosis?. Respiration, 2017, 93, 79-80.	1.2	1
260	Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control. , 2017, , 389-410.		1
261	1275. Will an App-Optimized HIV Self-testing Strategy Work for South Africans? Results From a Large Cohort Study. Open Forum Infectious Diseases, 2018, 5, S388-S388.	0.4	1
262	â€˜Mind the gap': detecting the missing TB cases through active case finding. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1115-1115.	0.6	1
263	Does the use of adjunct urine lipopolysaccharide lipoarabinomannan in HIV-infected hospitalized patients reduce the utilization of healthcare resources? A post hoc analysis of the LAM multi-country randomized controlled trial. International Journal of Infectious Diseases, 2019, 79, 37-43.	1.5	1
264	Challenging the management of drug-resistant tuberculosis â€" Authors' reply. Lancet, The, 2020, 395, 783-784.	6.3	1
265	The child ecosystem and childhood pulmonary tuberculosis: A South African perspective. Pediatric Pulmonology, 2021, 56, 2212-2222.	1.0	1
266	South African guideline for the management of community-acquired pneumonia in adults. Southern African Journal of Infectious Diseases, 2018, 33, 5-27.	0.3	1
267	Impact of a personalised, digital, HIV self-testing app-based program on linkages and new infections in the township populations of South Africa. BMJ Global Health, 2021, 6, .	2.0	1
268	Extensively drug-resistant Mycobacterium tuberculosis: what are these bugs up to in India?. Indian Journal of Medical Research, 2009, 130, 357-8.	0.4	1
269	A historical review of XDR tuberculosis in the Western Cape province of South Africa. South African Medical Journal, 2011, 101, 636-8.	0.2	1
270	Treatment Response in Pediatric Pulmonary Tuberculosisâ€"A Prospective Longitudinal Study. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 329-336.	0.6	1

#	ARTICLE	IF	CITATIONS
271	Recommendations for the use of bronchial thermoplasty in the management of severe asthma. South African Medical Journal, 2015, 105, 726-32.	0.2	1
272	Reply to Lu et al.. Journal of Infectious Diseases, 2005, 192, 1674-1675.	1.9	0
273	Expression of IL-4 mRNA in peripheral blood mononuclear cells from normal donors in relation to expression of TLR2. Immunology Letters, 2006, 106, 194-197.	1.1	0
274	Extensively drug-resistant tuberculosis in South Africa â€" Authors' reply. Lancet, The, 2010, 376, 681-682.	6.3	0
275	Indications for the use of bronchial thermoplasty in severe asthma. South African Medical Journal, 2015, 105, 808.	0.2	0
276	The Multistep Tuberculosis Diagnostic Cascade. More Than Meets the Eye. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 809-811.	2.5	0
277	Using Urine Lipoarabinomannan (LAM) in Practice: The Incremental Yield of Urine LAM and Xpert MTB/RIF Testing in Hospitalized HIV-Infected Patients. Chest, 2017, 152, A200.	0.4	0
278	The tip of the iceberg: Alarming increase in the detection of MDR-TB. South African Respiratory Journal, 2017, 23, 26.	0.0	0
279	M/XDRâ€‑TB treatment perspective: How to avoid mountains of pills via digital technologies â€" Reply. Respirology, 2018, 23, 637-637.	1.3	0
280	Improving outcomes in patients with non-tuberculous mycobacterial disease: is there light at the end of the tunnel?. European Respiratory Journal, 2019, 54, 1901149.	3.1	0
281	P032â€¦Alone but supported with an innovative HIV self-testing app: qualitative results from a large cohort study in south africa. , 2019, , .		0
282	Differential RD-1-specific IFN-Î³ host responses to diverse Mycobacterium tuberculosis strains in HIV-uninfected persons may be explained by genotypic variation in the ESX-1 region. International Journal of Infectious Diseases, 2020, 96, 240-243.	1.5	0
283	Lung health in Africa: African solutions for African challenges - to infinity and beyond. African Journal of Thoracic and Critical Care Medicine, 2018, 24, .	0.3	0